Last updated on July 2018

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

Brief description of study

This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of E6007 once daily for 8 weeks in Japanese participants with moderate active ulcerative colitis. Participants will be stratified by prior therapeutic treatment and Mayo score at Baseline, and will be randomized 1:1:1 to receive E6007 30 milligrams (mg), E6007 60 mg or placebo.

Clinical Study Identifier: NCT03018054

Contact Investigators or Research Sites near you

Start Over

Public Relations Group

EA Pharma Trial Site #1
Osakasayama, Japan
  Connect »